Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma IncfiledCriticalBiogen Ma Inc
Publication of AR118304A1publicationCriticalpatent/AR118304A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Se proporcionan composiciones farmacéuticas que contienen anticuerpos anti-LINGO-1 o fragmentos de unión a LINGO-1 de estos. Estas composiciones farmacéuticas son útiles en el tratamiento de enfermedades desmielinizantes del SNC, tales como esclerosis múltiple y neuritis óptica (por ejemplo, neuritis óptica aguda).Pharmaceutical compositions containing anti-LINGO-1 antibodies or LINGO-1 binding fragments of these are provided. These pharmaceutical compositions are useful in the treatment of CNS demyelinating diseases, such as multiple sclerosis and optic neuritis (eg, acute optic neuritis).